open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-23
Get Citation

Erlotinib therapy in advanced non small-cell lung cancer

Joanna Gazdulska, Maciej Bryl, Rodryg Ramlau

open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-23

Abstract

Erlotinib is one of epithelial growth factor receptor tyrosine kinase inhibitors. Treatment of selected patient groups may result in prolonged survival time and improved quality of life during therapy. Patients who benefit most from this therapy are those with confirmed activating mutations within the EGFR gene, in good general condition. These drugs are well tolerated and do not require hospitalization, which is very important for the patients and their families We present the case of a male with advanced non small cell lung cancer who receives erlotinib.

Abstract

Erlotinib is one of epithelial growth factor receptor tyrosine kinase inhibitors. Treatment of selected patient groups may result in prolonged survival time and improved quality of life during therapy. Patients who benefit most from this therapy are those with confirmed activating mutations within the EGFR gene, in good general condition. These drugs are well tolerated and do not require hospitalization, which is very important for the patients and their families We present the case of a male with advanced non small cell lung cancer who receives erlotinib.

Get Citation

Keywords

erlotinib, non small cell lung cancer, EGFR, target therapy

About this article
Title

Erlotinib therapy in advanced non small-cell lung cancer

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. G (2014)

Pages

42-45

Published online

2015-03-23

Keywords

erlotinib
non small cell lung cancer
EGFR
target therapy

Authors

Joanna Gazdulska
Maciej Bryl
Rodryg Ramlau

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl